epigallocatechin gallate has been researched along with Intestinal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, J; Liu, X; Mackenzie, GG; Su, Z; Wang, Y; Wei, R; Wu, F | 1 |
| Barañao, RI; Bastón, JI; Bilotas, MA; Meresman, GF; Olivares, CN; Ricci, AG; Singla, JJ | 1 |
2 other study(ies) available for epigallocatechin gallate and Intestinal Diseases
| Article | Year |
|---|---|
(-)-Epigallocatechin-3-gallate mitigates cyclophosphamide-induced intestinal injury by modulating the tight junctions, inflammation and dysbiosis in mice.
Topics: Animals; Catechin; Cyclophosphamide; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Intestinal Diseases; Male; Mice; Mice, Inbred ICR; Tight Junctions | 2021 |
Natural therapies assessment for the treatment of endometriosis.
Topics: Angiogenesis Inhibitors; Animals; Antioxidants; Apoptosis; Catechin; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Female; Humans; Injections, Intraperitoneal; Intestinal Diseases; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Resveratrol; Stilbenes | 2013 |